UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stock Position in InMode Ltd. (NASDAQ:INMD)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of InMode Ltd. (NASDAQ:INMD) by 54.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 125,480 shares of the healthcare company’s stock after acquiring an additional 44,058 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.15% of InMode worth $2,127,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Systematic Financial Management LP lifted its position in shares of InMode by 34.5% during the second quarter. Systematic Financial Management LP now owns 866,619 shares of the healthcare company’s stock worth $15,807,000 after purchasing an additional 222,532 shares in the last quarter. ARK Investment Management LLC lifted its holdings in InMode by 35.0% during the 2nd quarter. ARK Investment Management LLC now owns 124,905 shares of the healthcare company’s stock worth $2,278,000 after buying an additional 32,369 shares in the last quarter. Hsbc Holdings PLC boosted its position in InMode by 129.7% in the 2nd quarter. Hsbc Holdings PLC now owns 90,280 shares of the healthcare company’s stock valued at $1,659,000 after buying an additional 50,974 shares during the period. North Growth Management Ltd. grew its stake in shares of InMode by 11.9% in the second quarter. North Growth Management Ltd. now owns 593,000 shares of the healthcare company’s stock worth $10,821,000 after acquiring an additional 63,000 shares in the last quarter. Finally, Means Investment CO. Inc. acquired a new position in shares of InMode in the second quarter worth $285,000. 68.04% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Needham & Company LLC reiterated a “hold” rating on shares of InMode in a research note on Thursday, October 31st. Barclays decreased their price objective on InMode from $29.00 to $27.00 and set an “overweight” rating for the company in a research note on Monday, October 14th. Finally, BTIG Research assumed coverage on shares of InMode in a research note on Thursday, October 17th. They set a “buy” rating and a $25.00 target price on the stock. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $22.60.

InMode Stock Performance

NASDAQ:INMD opened at $18.26 on Monday. InMode Ltd. has a 1 year low of $14.87 and a 1 year high of $26.80. The stock has a market cap of $1.53 billion, a P/E ratio of 9.87 and a beta of 2.07. The stock has a 50-day simple moving average of $18.08 and a 200-day simple moving average of $17.49.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.